Last reviewed · How we verify
A Comparison of the Efficacy of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5 mg 1 Inhalation b.i.d. Plus As-needed) and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults. A Randomized, Open, Parallel-group, Multicentre 26-weeks Study
The purpose of the study is to compare the efficacy of a flexible dose of Symbicort (budesonide/formoterol) with conventional stepwise best standard treatment in patients with persistent asthma.
Details
| Lead sponsor | AstraZeneca |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 1900 |
| Start date | 2004-09 |
| Completion | 2006-10 |
Conditions
- Asthma
Interventions
- Budesonide/Formoterol Turbuhaler
- Conventional Best Asthma Therapy
Primary outcomes
- Time to first severe asthma exacerbation
Countries
Denmark, Finland, Norway